Skip to main content
Arcellx, Inc. logo

Arcellx, Inc. — Investor Relations & Filings

Ticker · ACLX ISIN · US03940C1009 US Manufacturing
Open in API
Filings indexed 411 across all filing types
Latest filing 2026-04-28 Transaction in Own Shar…
Country US United States of America
Listing US ACLX

About Arcellx, Inc.

https://www.arcellx.com/

Arcellx, Inc. is a clinical-stage biotechnology company that develops immunotherapies for patients with cancer and autoimmune diseases. The company is focused on reimagining cell therapy through its proprietary D-Domain technology. This technology is the foundation for its two main platforms: ddCAR, which produces autologous and allogeneic CAR-T therapies, and ARC-SparX, which involves controllable and adaptable cell therapies. Arcellx's lead investigational product, CART-ddBCMA, is in clinical development for the treatment of relapsed or refractory multiple myeloma. The company aims to create therapies that are safer, more effective, and more broadly accessible.

Recent filings

Filing Released Lang Actions
S-8 POS - Arcellx, Inc. (0001786205) (Filer)
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment to multiple Form S-8 Registration Statements filed with the SEC. It details the deregistration of securities that remain unissued under these registration statements following a merger transaction. The document is a formal SEC filing related to share registration and deregistration, specifically concerning equity incentive plans and employee stock purchase plans. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. It is a regulatory filing about capital structure changes (deregistration of shares) but is not a direct capital/financing update like a fundraising announcement. Given the nature of the document as a post-effective amendment to registration statements and deregistration of securities, the most appropriate classification is Transaction in Own Shares (POS), which covers share repurchase/issuance or deregistration activities related to the company's own shares. The document length and content confirm it is not a brief announcement but a substantive filing. Confidence is high due to clear SEC form references and content focus on share deregistration.
2026-04-28 English
25-NSE - Arcellx, Inc. (0001786205) (Subject)
Delisting Announcement
2026-04-28 English
10-K/A - Arcellx, Inc. (0001786205) (Filer)
Annual Report FY 2025
2026-04-24 English
SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - Arcellx, Inc. (0001786205) (Issuer)
Director's Dealing
2026-03-19 English
4 - ARCELLX, INC. (0001786205) (Filer)
Director's Dealing
2026-03-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.